Breaking News, Collaborations & Alliances

Vectura Earns $5M Novartis Milestone for Enerzair Breezhaler

Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class fixed-dose combination maintenance treatment for uncontrolled asthma.

By: Contract Pharma

Contract Pharma Staff

Novartis received approval from the European Commission for Enerzair Breezhaler, triggering a $5 million milestone payment to Vectura Group plc, an inhalation CDMO. Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class LABA/LAMA/ICS fixed-dose combination maintenance treatment for patients whose asthma is uncontrolled with LABA/ICS. On 29th June, Enerzair Breezhaler was approved for use in Japan, triggering a further $1.25 million milestone payment to Vectura. Vectura al...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters